Overview

As a stakeholder in the health and life sciences industry, you work every day to improve human health and enhance patient care. Our national health and life sciences industry team partners with you to advance your objectives. We understand how changing business models, disruptive technologies and increased data security challenges, among other developments, impact your organization, and we work to help you overcome challenges and seize opportunities in this continuously evolving landscape. Whether we are collaborating with a pharmaceutical or medical device manufacturer to guide a new product through the development and approval life cycle or helping health care providers implement their strategic objectives, we provide business-minded solutions to address your most pressing challenges. Our team handles major strategic transactions; represents clients in high-stakes governmental investigations; negotiates cost-saving outsourcing arrangements, IP licenses, software and AI agreements, and research and collaboration agreements; and executes public policy and government affairs strategies for health care, life sciences and patient advocacy organizations. Our professionals include former in-house counsel at health systems and global pharmaceutical and device companies, former congressional and federal agency health policy specialists, and Department of Justice attorneys.

Insights & Events

Latest

Speaking Engagement Recap March 25, 2025

AI Governance and Risk Management: Key Considerations and Traps for the Unwary

Complimentary Insurance Seminar
1 min read  
最新 March 2025

The Latest on Pharmaceutical Company-Sponsored Diagnostic Testing Programs

OIG’s Second Favorable Opinion Regarding Free Genetic Testing and Counseling: Advisory Opinion No. 24-12
8 min read  
媒体报道 March 2025

Scott Kosnoff Discusses Virginia AI Bill, Future State AI Legislation With Law360

2 min read  
最新 March 2025

EPA Rolls Back Regulations From Climate Change to ‘Waters of the United States’

PFAS and Superfund Do Not Make the List
4 min read  
Speaking Engagement Recap March 12, 2025

The Current State of Pediatric Research: Challenges, Opportunities and Action

Society for Pediatric Research Advocacy Committee
1 min read  
最新 March 2025

Amid Deteriorating Budget Picture, Divided Minnesota Legislature Faces Difficult Budget Negotiations

Minnesota Legislative Update
6 min read  
March 2025

How You Can Help Immigrant Neighbors Who Are in Need

1 min read  
News February 2025

Faegre Drinker Team Secures Favorable First Circuit Ruling for Regeneron in False Claims Act Case

2 min read  
Press Release February 2025

Faegre Drinker Continues Expansion of West Coast Litigation Team, Welcoming Antitrust Partner Heather Burke

2 min read  
Recorded Webinar February 13, 2025 CLE

Inside the FDA Under Trump 2.0 Transition: What We Know & What to Expect From a Career FDA Attorney - Webinar

1 min read  
Insights
最新 March 2025

The Latest on Pharmaceutical Company-Sponsored Diagnostic Testing Programs

OIG’s Second Favorable Opinion Regarding Free Genetic Testing and Counseling: Advisory Opinion No. 24-12
8 min read  
媒体报道 March 2025

Scott Kosnoff Discusses Virginia AI Bill, Future State AI Legislation With Law360

2 min read  
最新 March 2025

EPA Rolls Back Regulations From Climate Change to ‘Waters of the United States’

PFAS and Superfund Do Not Make the List
4 min read  
最新 March 2025

Amid Deteriorating Budget Picture, Divided Minnesota Legislature Faces Difficult Budget Negotiations

Minnesota Legislative Update
6 min read  
March 2025

How You Can Help Immigrant Neighbors Who Are in Need

1 min read  
最新 March 2025

Trump’s EO Seeks to Eliminate ‘Unconstitutional’ Regulations; EU Commission Scraps AI Liability Directive; Lawsuit Alleges Racial Discrimination by Meta’s Ad Algorithms for Higher Education; and More

Artificial Intelligence Briefing
7 min read  
发表文章 March 2025

Breaking the Silence: Challenges and Opportunities in Pediatric Drug Development

1 min read  
最新 March 2025

HHS Rescission of the Richardson Waiver and Unintended Legal Consequences for Drug and Device Manufacturers

After the Department’s Recission of the Richardson Waiver, Drug and Device Industry Loses Powerful Check Against FDA Overreach
6 min read  
最新 March 2025

NIH Funding Guidance; FDA Reinstates Key Staff Amid Industry Pressure; Make America Healthy Again Commission; and the Latest on Tariffs

Biopharma & Medical Devices Briefing
7 min read  
最新 March 2025

Trump Administration’s America First Investment Policy to Bring Changes to CFIUS and Outbound Investment Reviews

New Risks and Opportunities for Both Foreign and Domestic Investors
6 min read  

Related Legal Services